EGFR and lung adenocarcinoma: Loss of Gene 33, both homozygous deletion and haploinsufficiency, accelerates the initiation and progression of lung adenocarcinoma driven by transgenic expression of mutant EGFRs (L858R or del-746-750) in mice, likely a result of increased MAPK activity due to reduced inhibition of EGFR [34].